N-Acetyl Cysteine (NAC) para Helicobacter pylori Infection

NAC (600-1,200 mg/day) may improve H. pylori eradication rates by disrupting biofilm. Small studies show improved eradication when combined with standard therapy.

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dn\u002Dacetyl\u002Dcysteine\u0026condition\u003Dh\u002Dpylori'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

Conclusión

NAC (600-1,200 mg/day) may improve H. pylori eradication rates by disrupting biofilm. Small studies show improved eradication when combined with standard therapy.

Key Study Findings

In Vitro

Berberrubine inhibits Helicobacter pylori by inducing oxidative stress and impairing membrane integrity.

Dose: MIC 11 μg/mL vs: None Outcome: anti-Helicobacter pylori activity Efecto: None None

Población: None

Other

Correction to "N-Acetylcysteine Reduces ROS-Mediated Oxidative DNA Damage and PI3K/Akt Pathway Activation Induced by Helicobacter …

Dose: None vs: None Outcome: None Efecto: None None

Población: Published erratum (correction notice)

Review

Posttranslational modifications in Helicobacter pylori-associated gastric pathogenesis: Bridging inflammation and carcinogenesis.

Dose: None vs: None Outcome: None Efecto: None None

Población: None

Other

Liposomal Drug Delivery against Helicobacter pylori Using Furazolidone and N-Acetyl Cysteine in Augmented Therapy.

Dose: None vs: None Outcome: Cancer outcomes Efecto: None None

Población: Cancer patients

In Vitro

Helicobacter pylori infection selectively attenuates endothelial function in male mice via exosomes-mediated ROS production.

Dose: None vs: None Outcome: choline levels/cognition Efecto: None None

Población: Mice

Other

α-Lipoic Acid Inhibits Apoptosis by Suppressing the Loss of Ku Proteins in Helicobacter pylori-Infected Human …

Dose: None vs: None Outcome: None Efecto: None None

Población: None

Key Statistics

Estudios

250

Participantes

↑

Positive

Calificación

Referenced Papers

Berberrubine inhibits Helicobacter pylori by inducing oxidative stress and impairing membrane integrity. Other

mLife 2026

Posttranslational modifications in Helicobacter pylori-associated gastric pathogenesis: Bridging inflammation and carcinogenesis. Review

Biochimica et biophysica … 2025 1 citas

Correction to "N-Acetylcysteine Reduces ROS-Mediated Oxidative DNA Damage and PI3K/Akt Pathway Activation Induced by Helicobacter pylori Infection". Other

Oxidative medicine and … 2025

Liposomal Drug Delivery against Helicobacter pylori Using Furazolidone and N-Acetyl Cysteine in Augmented Therapy. Other

Pharmaceutics 2024 8 citas

Helicobacter pylori infection selectively attenuates endothelial function in male mice via exosomes-mediated ROS production. Other

Frontiers in cellular … 2023 7 citas

CagA+ Helicobacter pylori, Not CagA- Helicobacter pylori, Infection Impairs Endothelial Function Through Exosomes-Mediated ROS Formation. Other

Frontiers in cardiovascular … 2022 27 citas

α-Lipoic Acid Inhibits Apoptosis by Suppressing the Loss of Ku Proteins in Helicobacter pylori-Infected Human Gastric Epithelial Cells. Other

Nutrients 2022 11 citas

Activity of Sodium Lauryl Sulfate, Rhamnolipids, and N-Acetylcysteine Against Biofilms of Five Common Pathogens. Other

Microbial drug resistance … 2020 34 citas

Comparison of the effect of clarithromycin triple therapy with or without N-acetylcysteine in the eradication of Helicobacter pylori: a randomized … Other

Therapeutic advances in … 2020 7 citas

Synthesis of Fucose Derivatives with Thiol Motifs towards Suicide Inhibition of Helicobacter pylori. Other

Molecules (Basel, Switzerland) 2020

Multidrug resistance in Helicobacter pylori: current state and future directions. Review

Expert review of … 2019 85 citas

N-acetylcysteine as an adjuvant therapy for Helicobacter pylori eradication. Meta-Analysis

The Cochrane database … 2019 21 citas

N-Acetylcysteine Reduces ROS-Mediated Oxidative DNA Damage and PI3K/Akt Pathway Activation Induced by Helicobacter pylori Infection. Other

Oxidative medicine and … 2018 93 citas

The effect of antioxidants on Helicobacter pylori eradication: A systematic review with meta-analysis. Meta-Analysis

Helicobacter 2018 18 citas

N-acetylcysteine prevents the development of gastritis induced by Helicobacter pylori infection. Other

Journal of microbiology … 2017 16 citas

Structural Insights into Polymorphic ABO Glycan Binding by Helicobacter pylori. Other

Cell host & … 2016 101 citas

Helicobacter pylori Activates IL-6-STAT3 Signaling in Human Gastric Cancer Cells: Potential Roles for Reactive Oxygen Species. Other

Helicobacter 2016 60 citas

Supplementation with Angelica keiskei inhibits expression of inflammatory mediators in the gastric mucosa of Helicobacter pylori-infected mice. Other

Nutrition research (New … 2016 25 citas

Helicobacter pylori induces Snail expression through ROS-mediated activation of Erk and inactivation of GSK-3β in human gastric cancer cells. Other

Molecular carcinogenesis 2016 18 citas

Effects of N-acetylcysteine on First-Line Sequential Therapy for Helicobacter pylori Infection: A Randomized Controlled Pilot Trial. RCT

Gut and liver 2016 17 citas

Helicobacter pylori induces IL-1β and IL-18 production in human monocytic cell line through activation of NLRP3 inflammasome via ROS signaling … Other

Pathogens and disease 2015 64 citas

Current Helicobacter pylori treatment in 2014. Review

World journal of … 2015 21 citas

Oxidative DNA Damage Response in Helicobacter pylori-Infected Mongolian Gerbils. Other

Journal of cancer … 2013 10 citas

Review article: biofilm formation by Helicobacter pylori as a target for eradication of resistant infection. Review

Alimentary pharmacology & … 2012 104 citas

Update on triple therapy for eradication of Helicobacter pylori: current status of the art. Other

Clinical and experimental … 2012 1 citas

The potential role of N-acetylcysteine for the treatment of Helicobacter pylori. Other

Journal of clinical … 2011 34 citas

Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. RCT

Clinical gastroenterology and … 2010 103 citas

Chios mastic, a natural supplement for zinc to enhance male sexuality and prostate function. Other

Pharmaceutical biology 2010 16 citas

Peptide Extracts from Cultures of Certain Lactobacilli Inhibit Helicobacter pylori. Other

Probiotics and antimicrobial … 2010 9 citas

N-acetylcysteine: multiple clinical applications. Review

American family physician 2009

A curcumin-based 1-week triple therapy for eradication of Helicobacter pylori infection: something to learn from failure? CCT

Helicobacter 2007 130 citas

Premedication with pronase or N-acetylcysteine improves visibility during gastroendoscopy: an endoscopist-blinded, prospective, randomized study. RCT

World journal of … 2007 77 citas

Effect of selenium- and glutathione-enriched yeast supplementation on a combined atherosclerosis and diabetes hamster model. Other

Journal of agricultural … 2007 44 citas

Thiol-oxidant monochloramine mobilizes intracellular Ca2+ in parietal cells of rabbit gastric glands. Other

American journal of … 2007 11 citas

N-acetylcysteine, a novel treatment for Helicobacter pylori infection. Other

Digestive diseases and … 2004 53 citas

Cellular mucosal defense is attenuated with chronicity of Helicobacter pylori infection. Other

Digestive diseases and … 2004 4 citas

Role of NF-kappaB and AP-1 on Helicobater pylori-induced IL-8 expression in AGS cells. Other

Digestive diseases and … 2003 69 citas

Transcriptional regulation by thiol compounds in Helicobacter pylori-induced interleukin-8 production in human gastric epithelial cells. Other

Annals of the … 2002 30 citas

Oxidant-sensitive transcription factor and cyclooxygenase-2 by Helicobacter pylori stimulation in human gastric cancer cells. Other

Journal of environmental … 2002

The antioxidant effect of rebamipide on oxygen free radical production by H. pylori-activated human neutrophils: in comparison with N-acetylcysteine, ascorbic … Other

Pharmacological research 2001 25 citas

[Omeprazole/amoxicillin: improved eradication of Helicobacter pylori in smokers because of N-acetylcysteine]. RCT

Schweizerische medizinische Wochenschrift 1994 22 citas

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosificaciones de uso común

general:: 600-1,200 mg/day in divided doses
hpyloriadjunct:: 600 mg twice daily alongside standard triple therapy
antioxidantsupport:: 600-900 mg/day

Límite superior: Generally well-tolerated up to 1,800 mg/day; higher doses used in clinical settings

Dosificaciones estudiadas en la investigación

Dosificación	Duración	Efecto	N
MIC 11 μg/mL	--	Positive	--
None	--	Mixed	--
None	--	Mixed	--
None	--	Positive	--
None	--	Mixed	--
None	--	Mixed	--
None	--	Negative	--
None	--	Positive	--

Mejor momento para tomar: With or without food; divide doses throughout the day

Safety & Side Effects

Efectos secundarios reportados

⚠ Nausea and vomiting (most common, especially at higher doses)
⚠ Diarrhea
⚠ Unpleasant sulfur taste/odor
⚠ Headache

Interacciones conocidas

● Nitroglycerin (NAC may enhance vasodilatory effects; risk of hypotension)
● Activated charcoal (may reduce NAC absorption)
● Anticoagulants (NAC may have mild antiplatelet effects)
● ACE inhibitors (additive hypotensive effect with nitroglycerin combination)

Ingesta máxima tolerable: Generally well-tolerated up to 1,800 mg/day; higher doses used in clinical settings

Consulte siempre a su profesional de salud antes de comenzar cualquier suplemento.Siempre consulte a su profesional de salud antes de comenzar cualquier suplemento.

Frequently Asked Questions

Does N-Acetyl Cysteine (NAC) help with Helicobacter pylori Infection?

Based on 3 studies with 250 participants, there is limited but promising evidence that N-Acetyl Cysteine (NAC) may support Helicobacter pylori Infection management. Our evidence grade is C (Some Evidence).

How much N-Acetyl Cysteine (NAC) should I take for Helicobacter pylori Infection?

Studies have used various dosages. A commonly studied range is 600-1,200 mg/day in divided doses. Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of N-Acetyl Cysteine (NAC)?

Reported side effects may include Nausea and vomiting (most common, especially at higher doses), Diarrhea, Unpleasant sulfur taste/odor, Headache. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for N-Acetyl Cysteine (NAC) and Helicobacter pylori Infection?

We rate the evidence as Grade C (Some Evidence). This rating is based on 3 peer-reviewed studies with 250 total participants. The overall direction of effect is positive.

Related Evidence

Otros ingredientes para Helicobacter pylori Infection

Lactobacillus gasseri B

N-Acetyl Cysteine (NAC) para otras condiciones

Inflammatory Bowel Disease (IBD) — General D

Veredicto rápido

NAC (600-1,200 mg/day) may improve H. pylori eradication rates by disrupting biofilm. Small studies show improved eradication when combined with standard therapy.

Evidence Strength52%

Moderate confidence

Desglose de estudios

RCT (4)Meta (2)Other (0)

Comparar alternativas

Vea cómo se comparan otros ingredientes para esta condición.

Ver todos los ingredientes para Helicobacter pylori Infection

Más información

Aviso legal FDA: Estas declaraciones no han sido evaluadas por la Food and Drug Administration. Los productos y la información en este sitio web no están destinados a diagnosticar, tratar, curar ni prevenir ninguna enfermedad. Las calificaciones de evidencia presentadas se basan en nuestro análisis de investigación publicada revisada por pares y no constituyen consejo médico. Siempre consulte a su profesional de salud antes de comenzar cualquier régimen de suplementos.